Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells, the cells in the body that normally fight infection. It is the most common cancer in children. Over the last several decades, advances in the treatment and supportive care of pediatric ALL have dramatically increased its 5-year survival rate to about 90%. Despite these improvements, a considerable number of children with ALL continue to relapse following standard treatment. Accurately diagnosing those patients who are high-risk for relapse and treating them with targeted therapies may greatly enhance their outcomes.

The ALL project has expanded, and more details can be found below regarding the Pilot, Phase II, and Phase III. Please refer to the TARGET Publication Guidelines page to see which datasets are available without restrictions on their use in publications or presentations.

Last updated: March 17, 2020